Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. disclosed a share reduction plan by its major shareholder, Ruizhong Life, which intends to reduce its holdings by up to 3,789,267 shares (3% of total share capital) between June 4 and September 3, 2025 [1] Summary by Relevant Sections - Share Reduction Plan - Ruizhong Life plans to reduce its holdings by a maximum of 3,789,267 shares, representing 3% of the total share capital [1] - Actual Reduction - As of September 3, 2025, Ruizhong Life has reduced its holdings by 1,263,000 shares, accounting for 0.7692% of the total shares (0.7834% considering the impact of share buybacks) [1] - Impact on Company - The reduction did not lead to a change in the company's control and did not significantly affect the company's governance or operations [1]

Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. plans to repurchase its shares using raised funds, self-owned funds, and self-raised funds through centralized bidding, with a total repurchase amount between RMB 100 million and RMB 200 million [1][2]. Summary by Sections Share Repurchase Plan - The company will use a total of no less than RMB 100 million and no more than RMB 200 million for the share repurchase, with raised funds accounting for no less than RMB 70 million and no more than RMB 140 million [2]. - The maximum repurchase price is set at RMB 45.50 per share, with the repurchase period not exceeding 12 months from the date of shareholder meeting approval [2]. Adjustments Post-Equity Distribution - Following the implementation of the 2024 annual equity distribution, the maximum repurchase price will be adjusted to RMB 34.84 per share, effective from July 14, 2025 [3]. - The repurchase will include shares for employee stock ownership plans or equity incentives, with specific quantities and funding sources detailed in the report [3][4]. Debt Creditor Information - Creditors have the right to request debt repayment or guarantees within 30 days of notification or 45 days from the announcement date, with the company continuing to fulfill obligations as per original debt agreements [4][5]. - Required materials for debt claims include contracts and identification documents, with specific submission methods outlined [5].

Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. has announced a share repurchase plan using raised funds, self-owned funds, and self-raised funds through centralized bidding [1]. Group 1: Share Repurchase Announcement - The company held its sixth board meeting on June 23, 2025, where it approved the share repurchase plan [1]. - The details of the share repurchase plan were disclosed on June 24, 2025, on the Giant Tide Information Network [1]. Group 2: Shareholder Information - The announcement includes the top ten shareholders and their respective shareholding quantities and proportions [1]. - The top shareholder is "Hesheng Wealth (Beijing) Fund Management Co., Ltd. - Hesheng Wealth Selected No. 7 Private Securities Investment Fund" [1]. - The top ten unrestricted shareholders include the same entities as the top ten shareholders, indicating a concentration of ownership [1].